DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • South Korea
  • /
  • Pharmaceuticals & Biotech
Author Program NEWCreate Narrative
A206650 logo

EuBiologics Co., Ltd. Stock Price

KOSDAQ:A206650 Community·₩314.2b Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 1 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

A206650 Share Price Performance

₩0
-14260.00 (-100.00%)
​
₩0
-14260.00 (-100.00%)
​
Price ₩0
Thu, 10 Sep 26
Share Pricen/a

A206650 Community Narratives

There are no narratives available yet.
Create Narrative
There are no community narratives available.

Trending Discussion

No trending discussion available.

Recently Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Minimal risk with weak fundamentals.

1 Risk
0 Rewards
View Full Analysis

EuBiologics Co., Ltd. Key Details

₩96.0b

Revenue

₩0

Cost of Revenue

₩96.0b

Gross Profit

₩71.2b

Other Expenses

₩24.9b

Earnings

Last Reported Earnings
Dec 31, 2024
Next Reporting Earnings
n/a
0
0%
0%
0%
View Full Analysis

About A206650

Founded
2010
Employees
n/a
CEO
Yeong-Ok Baik
WebsiteView website
eubiologics.com

EuBiologics Co., Ltd., a biopharmaceutical company, focuses on developing vaccines against global pandemic and bacterial vaccines primarily in South Korea. It offers inactivated oral cholera vaccine under the Euvichol, Euvichol-Plus, and Euvichol-S names; and EuCorVac-19, a recombinant protein vaccine. The company also provides EcML that is used as a vaccine adjuvant, directly activating antigen presenting cell expressing TLR 4 agonist, stimulating the production of cytokines and co-stimulatory molecules. In addition, it offers carrier protein vaccine under the rCRM197 name; and biopharmaceutical contract research and manufacturing, and contract testing services. Further, the company engages in the development of and support for the manufacturing technologies of biomedicines. The company was founded in 2010 and is headquartered in Seoul, South Korea.

Recent A206650 News & Updates

Recent updates

No updates

EuBiologics Co., Ltd. Competitors

A207940 logo

Samsung BiologicsLtd

Symbol: KOSE:A207940
Market cap: ₩65.8t
A068270 logo

Celltrion

Symbol: KOSE:A068270
Market cap: ₩43.4t
A196170 logo

ALTEOGEN

Symbol: KOSDAQ:A196170
Market cap: ₩19.3t
A0126Z0 logo

Samsung Epis Holdings

Symbol: KOSE:A0126Z0
Market cap: ₩8.7t
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide